# Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

> **NCT01085812** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 734 (actual)

## Conditions studied

- Depression
- Major Depressive Disorder

## Interventions

- **DRUG:** Levomilnacipran ER
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01085812
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 734 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01085812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01085812, "Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01085812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*